What Happened?
Shares of medical device company Penumbra (NYSE: PEN) jumped 3.2% in the morning session after Needham upgraded the stock to 'Buy' from 'Hold' and set a price target of $326.
The firm expected the company's growth in 2026 to meaningfully accelerate due to upcoming product launches, including Thunderbolt and Ruby XL. The analyst also pointed to expected positive trial results and an easing of business challenges in China as reasons for the improved outlook. According to the research note, the Thunderbolt device should nearly double Penumbra's revenue per stroke procedure while also driving stronger growth and gross margin improvement. Needham noted that Penumbra was positioned for a significant upside to consensus earnings estimates for 2026.
After the initial pop the shares cooled down to $257.86, up 3.5% from previous close.
Is now the time to buy Penumbra? Access our full analysis report here.
What Is The Market Telling Us
Penumbra’s shares are somewhat volatile and have had 10 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 13 days ago when the stock dropped 2.5% on the news that the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, raising concerns about potential tariffs.
The probe, conducted under Section 232 of the Trade Expansion Act, examines whether imports of items like syringes, infusion pumps, and surgical instruments pose a national security risk. Such investigations can pave the way for new import duties, creating a significant overhang for the sector. The goal of potential tariffs would be to boost domestic manufacturing by increasing the cost of foreign goods. This development has introduced new uncertainty for the industry, leading to broad-based declines in the stocks of major manufacturers, including Baxter International and GE HealthCare, as investors weigh the potential impact on supply chains and costs.
Penumbra is up 7.4% since the beginning of the year, but at $257.86 per share, it is still trading 15.1% below its 52-week high of $303.76 from February 2025. Investors who bought $1,000 worth of Penumbra’s shares 5 years ago would now be looking at an investment worth $1,240.
Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free for active Edge members and will only take you a second.
